Asia Pacific Anti-hypertensive Drugs Market Size & Outlook
Related Markets
Asia Pacific anti-hypertensive drugs market highlights
- The Asia Pacific anti-hypertensive drugs market generated a revenue of USD 6,854.5 million in 2024.
- The market is expected to grow at a CAGR of 4.9% from 2025 to 2033.
- In terms of segment, angiotensin ii receptor blockers (arbs) was the largest revenue generating product in 2024.
- Fixed-Dose Combinations (FDCs) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 6,854.5 million |
| Market revenue in 2033 | USD 10,542.2 million |
| Growth rate | 4.9% (CAGR from 2025 to 2033) |
| Largest segment | Angiotensin ii receptor blockers (arbs) |
| Fastest growing segment | Fixed-Dose Combinations (FDCs) |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | ACE Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), Direct Renin Inhibitor, Calcium Channel Blockers, Diuretics, Mineralocorticoid Receptor Antagonists (MRAs), Beta-Blockers, Alpha-1 Blockers, Central Alpha-2 Agonists, Direct Vasodilators, Fixed-Dose Combinations (FDCs) |
| Key market players worldwide | Sanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 27.5% of the global anti-hypertensive drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,542.2 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-hypertensive Drugs Market Scope
Anti-hypertensive Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | https://www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Asia Pacific anti-hypertensive drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.
Angiotensin ii receptor blockers (arbs) was the largest segment with a revenue share of 25% in 2024. Horizon Databook has segmented the Asia Pacific anti-hypertensive drugs market based on ace inhibitors (aceis), angiotensin ii receptor blockers (arbs), direct renin inhibitor, calcium channel blockers, diuretics, mineralocorticoid receptor antagonists (mras), beta-blockers, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, fixed-dose combinations (fdcs) covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Asia Pacific anti-hypertensive drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific anti-hypertensive drugs market databook
-
Our clientele includes a mix of anti-hypertensive drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific anti-hypertensive drugs market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific anti-hypertensive drugs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific anti hypertensive drugs market report size, by country, 2021-2033 (US$M)
Asia Pacific Anti-hypertensive Drugs Market Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
